a



b



c



d

ETP treatment (μM)	Mean (a.u.)	SD (a.u.)	53BP1 Positive (%)
DMSO	4.67E+05	5.86E+05	33.3
15	8.65E+05	8.32E+05	58
30	1.07E+06	9.34E+05	69
60	9.70E+05	1.00E+06	59.2
90	6.64E+05	9.35E+05	39.5

e



f

ETP treatment (μM)	Mean (a.u.)	SD (a.u.)	γ-H2AX Positive (%)
DMSO	2.00E+02	1.51E+02	12.4
15	2.02E+02	3.05E+02	10.6
30	4.32E+02	4.60E+02	42.3
60	7.73E+02	8.64E+02	70.4
90	9.52E+02	9.02E+02	76.4

Supplementary Fig. 1) Detection of 53BP1 spot intensity in immune cells. 53BP1 positive cells were characterized in each treatment group for **a)** immune cell lines (Jurkat, BJAB, and THP-1) and **b)** $CD4^{+}$T cells, CD8+T cells, monocytes, and B cells. The same samples as in figures 2 and 3 are used. ETP Dose-response assay (0-90 µM) in Jurkat cell line for **c, d)** 53BP1 spot intensity and **e, f)** γ-H2AX mean nuclear intensity detection.

a

#	Donor	Age	Sex
1	ND791	30	F
2	ND782	31	F
3	Gt016	42	F
4	Gt024	47	M
5	Gt030	49	M
6	ND550	54	F
7	ND797	58	F
8	Gt004	62	M
9	ND334	67	F
10	Gt029	85	M

Supplementary Fig. 2) List of donors used in batch processing assay. a) For each listed donor in Figure 5, donors were identified by age and sex.